Zelira Therapeutics Receives Funding for FDA Clinical Trials

Zelira Therapeutics Ltd (ASX:$ZLD) has received the second tranche of US$819,000 funding from the 2011 Forman Trust, bringing the total funds received via the special purpose vehicle (SPV) to US$1.888 million. The funding is designated for Zelira to conduct FDA clinical trials for its proprietary and patent protected HOPE® 1 product. Zelira will manage the SPV as part of its business platform.

Executive Commentary on Funding and Clinical Trials

Zelira Therapeutics is pleased to announce the receipt of the second tranche of funding for our FDA clinical trials. This funding will support our efforts to conduct clinical trials for our proprietary HOPE® 1 product. We are committed to managing the special purpose vehicle as part of our business platform and look forward to subsequent rounds of closings from our ongoing fundraising activities to further support the HOPE 1 formal FDA clinical program.

Summary of Zelira Therapeutics Announcement

Zelira Therapeutics Ltd (ASX:ZLD) has received the second tranche of funding from the 2011 Forman Trust, totaling US$1.888 million via the special purpose vehicle (SPV) for conducting FDA clinical trials for its proprietary HOPE® 1 product. The company expects subsequent rounds of closings from its continuing fundraising efforts to support the HOPE 1 formal FDA clinical program. Zelira's focus on developing and clinically validating branded cannabinoid-based medicines for various medical conditions remains strong. The company's revenue-generating products and pipeline of candidates undergoing clinical development position it well to enter global markets. Zelira's commitment to managing the SPV and its ongoing efforts in clinical trials demonstrate its dedication to advancing cannabinoid-based medicines. The recent completion of a strategically designed multi-arm, head-to-head study targeting diabetic nerve pain further underscores the company's commitment to developing effective treatments. Additionally, Zelira's expansion of commercialization into Germany and its revenue-generating OTC products reflect its continued growth and market presence. The company's development of Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology and its assessment of opportunities for commercialization demonstrate its innovative approach to pharmaceutical grade solid oral dosage forms. Zelira's ongoing efforts and achievements position it as a leading global biopharmaceutical company in the cannabinoid-based medicines sector.